Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Responses to COVID-19 vaccination in patients with MDS and AML

David Sallman • 11 Dec 2021
ASH 2021
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes

In this video, David Sallman, MD, Moffitt Cancer Center, Tampa, FL, briefly highlights the response of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) to the COVID-19 vaccine. Dr Sallman mentions the need to obtain more data in the future on survival and risk of hospitalization, and emphasizes the importance of current data, which strongly supports vaccination in patients with hematological malignancies. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA, 2021.

More from David Sallman

2:08
Hematological response to frontline treatment in LR-MDS is associated with better OS
David Sallman • 9 Dec 2023
1:58
Canakinumab plus darbepoetin in patients with LR-MDS following ESA failure
David Sallman • 9 Dec 2023
2:49
Front-line treatment options for HR-MDS: can we move past azacitidine?
David Sallman • 9 Dec 2023
Transplantation & immunotherapies
Charles Craddock et al. • 4 Sep 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals